Fiche centre
Royal London Hospital
London — United Kingdom
Essais liés4clinical trials
VilleLondonlocalisation
PaysUnited Kingdomlocalisation
SourcelocaleCSV/MySQL
Informations
centreSynchronisé depuis ClinicalTrials.gov — NCT05418010
Essais cliniques associés
4| Molécule | Indication / population | Phase | NCT | Titre | Statut |
|---|---|---|---|---|---|
| Cladribine (MAVENCLAD®) | SEP | Phase 2/3 | NCT04695080 | ChariotMS - Cladribine to Halt Deterioration in People With Advanced Multiple Sclerosis | ACTIVE_NOT_RECRUITING |
| Tyruko Injectable Product | SEP | Phase 2 | NCT05418010 | Natalizumab for the Treatment of People With Inflammatory Demyelination Suggestive of Multiple Sclerosis, or Definite Multiple Sclerosis, at First Presentation (AttackMS) | RECRUITING |
| Prasinezumab | Parkinson | Phase 3 | NCT07174310 | PARAISO — A Study to Evaluate the Efficacy and Safety of Intravenous (IV) Prasinezumab in Participants With Early-Stage Parkinson's Disease | RECRUITING |
| Relief — Peripheral Nerve Stimulation Registry for Intractable Migraine Headache | Migraine | À vérifier | NCT02227758 | Relief — Peripheral Nerve Stimulation Registry for Intractable Migraine Headache | COMPLETED |